Phase III trials for aclidinium, a "me-too" antimuscarinic, in COPD (ACCLAIM I & II)

Jones et al randomized 1,647 people with moderate to severe COPD for the two trials, to receive either aclidinium inhaled (a potential tiotropium competitor) once daily or placebo for 1 year. Aclidinium improved FEV1 by ~65 mL. An absolute ~8% more people taking the drug achieved a 4-point SGRQ improvement over those taking placebo. Time to exacerbation was reduced slightly compared to placebo in one of the trials (the overall exacerbation rate was low). There were no serious adverse events. (n=1,647) Respiratory Research 2011;12:55. FREE FULL TEXT